Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
498
Employees498
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
498
Employees498

CYTK Key Statistics

Market cap
8.09B
Market cap8.09B
Price-Earnings ratio
-10.61
Price-Earnings ratio-10.61
Dividend yield
Dividend yield
Average volume
1.99M
Average volume1.99M
High today
$67.80
High today$67.80
Low today
$66.00
Low today$66.00
Open price
$66.45
Open price$66.45
Volume
1.29M
Volume1.29M
52 Week high
$67.98
52 Week high$67.98
52 Week low
$29.31
52 Week low$29.31

Stock Snapshot

The current Cytokinetics(CYTK) stock price is $66.18, with a market capitalization of 8.09B. The stock trades at a price-to-earnings (P/E) ratio of -10.61.

On 2025-11-18, Cytokinetics(CYTK) stock traded between a low of $66.00 and a high of $67.80. Shares are currently priced at $66.18, which is +0.3% above the low and -2.4% below the high.

Cytokinetics(CYTK) shares are trading with a volume of 1.29M, against a daily average of 1.99M.

During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $67.98 at its peak.

During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $67.98 at its peak.

CYTK News

TipRanks 1d
Cytokinetics supports AHA initiative to improve care for people living with HCM

Cytokinetics (CYTK) announced its support of a three-year initiative led by the American Heart Association, AHA, to address disparities in access to care, diagn...

Simply Wall St 4d
Cytokinetics Is Up 8.7% After Aficamten Surpasses Metoprolol in Key HCM Trial Outcomes Has The Bull Case Changed?

In November 2025, Cytokinetics announced that new data from the MAPLE-HCM trial showed aficamten provided greater improvements than metoprolol in multiple measu...

Cytokinetics Is Up 8.7% After Aficamten Surpasses Metoprolol in Key HCM Trial Outcomes Has The Bull Case Changed?
TipRanks 4d
Cytokinetics Appoints New Executive VP and CLO

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

Analyst ratings

81%

of 21 ratings
Buy
81%
Hold
19%
Sell
0%

More CYTK News

TipRanks 6d
Director’s Major Stock Sale at Cytokinetics Revealed!

New insider activity at Cytokinetics ( (CYTK) ) has taken place on November 12, 2025. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help yo...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.